UBS Group
PLYX icon

UBS Group’s Polaryx Therapeutics Inc PLYX Stock Holding History

UBS Group’s Portfolio PLYX Stock Details PLYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.02K Buy
4,355
+3,072
+239% +$6.69K ﹤0.01% 9170
2026
Q2 		$3.41K Sell
1,283
-12,196
-90% -$47.9K ﹤0.01% 9194
2026
Q1 		$102K Buy
+13,479
New +$87.1K ﹤0.01% 6992

Other funds holding PLYX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $87.3B AUM 22.01% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $225B AUM
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

UBS Group's PLYX Position: Q3 2026 in Review

UBS Group increased its Polaryx Therapeutics Inc (PLYX) stake by 239% in Q3 2026, buying an estimated $6.69K and bringing the position to 4,355 shares worth $9.02K. The position accounts for ﹤0.01% of the portfolio, ranked #9170.

UBS Group first reported a position in PLYX in Q1 2026 and has held it in 3 quarters since. The position peaked at $102K in Q1 2026. 11 funds tracked by Wall St. Rank hold PLYX as of Q3 2026.

  • UBS Group held 4,355 shares of Polaryx Therapeutics Inc worth $9.02K as of Q3 2026.
  • UBS Group bought 3,072 Polaryx Therapeutics Inc shares in Q3 2026, an estimated $6.69K.
  • Polaryx Therapeutics Inc made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #9170 holding.
  • UBS Group first reported a position in Polaryx Therapeutics Inc in Q1 2026 and has held it in 3 quarters since.
  • UBS Group's Polaryx Therapeutics Inc position peaked at $102K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Polaryx Therapeutics Inc as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.